September 15, 1999
VISX Price (9/14/99): $96 15/32
If VISX (Nasdaq: VISX) has its way, folks will be tossing out contact lenses and eyeglasses by the millions. The market leader in excimer laser corrective eye surgery has been looking good to shareholders.
However, not all Fools see eye-to-eye when it comes to VISX. While Barbara Eisner Bayer (TMF Venus) is an optimist, Rick Aristotle Munarriz (TMF Edible) is unsure of the company's prospects.
Once you've read the Duel and set your sights on a victor, check out our Duel Flashback that pitted Steven Jobs versus Bill Gates.
You Get to Vote!
Once you've read the arguments and the rebuttals, it's your time to cast your vote. We'll tabulate results each week and revisit them from time to time to see whether you were right! As always, we invite you to join us in the Dueling Fools Message board to continue the duel.
[Any suggestions, comments, praise, or flames, please send them along to the Dueling Fools Team.]
The performance of VISX stock has been as miraculous as the benefits its technology brings to the eyes. In 1998, investors saw their VISX stock rise 295%. So far in 1999, the stock is already up over 300%. Eye-opening growth even to the bearest of bears. Can this visionary company's phenomenal growth continue? I think so! After all, a future myopic is born every minute.
"We Make Things Clear" goes the VISX battlecry. Let me try to make things even clearer. The stock market was valuing VISX at a whopping $5.8 billion last week. To put this into perspective, I give you eyecare juggernaut Bausch & Lomb, selling for $2 billion less than VISX, yet sporting annual revenues ten times higher.